pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Inveltys
drug
save

loteprednol etabonate

Marketedupdated 3mo ago
by $ALC ALCON INC
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • drugLotemax SM4 co-mentions · 1 sources
  • drugLOTEPREDNOL ETABONATE AND TOBRAMYCIN4 co-mentions · 1 sources
  • tagApproval4 co-mentions · 1 sources
  • drugtobramycin2 co-mentions · 1 sources
  • drugTobi Podhaler2 co-mentions · 1 sources
  • drugTobrabact2 co-mentions · 1 sources

all catalysts(1)

approval · 1
Dec 10, 2025
approval
8mo ago
LOTEPREDNOL ETABONATE AND TOBRAMYCIN (LOTEPREDNOL ETABONATE) — FDA approval
loteprednol etabonate
→

Trials studying loteprednol etabonate

  • phase4Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Periodcompletedn=77
  • phase4Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejectioncompletedn=70

Patent cliff

source: FDA Orange Book
first barrier falls
May 3, 2033
~6.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (32)

  • Dec 23, 2036formulationUS 10596107
  • Jan 26, 2036formulationUS 11534395
  • May 3, 2033formulationUS 10058511
  • May 3, 2033formulationUS 10058511
  • May 3, 2033formulationUS 10646436
  • May 3, 2033formulationUS 10646437
  • May 3, 2033formulationUS 10688045
  • May 3, 2033formulationUS 10688045
  • May 3, 2033method-of-use (U-2985)US 10857096
  • May 3, 2033method-of-use (U-3011)US 10864219
  • May 3, 2033method-of-use (U-2985)US 10940108
  • May 3, 2033method-of-use (U-2985)US 10945948
  • May 3, 2033method-of-use (U-3117)US 10993908
  • May 3, 2033method-of-use (U-2985)US 11219596
  • May 3, 2033method-of-use (U-3279)US 11219597
  • May 3, 2033method-of-use (U-2985)US 11596599
  • May 3, 2033formulationUS 11642317
  • May 3, 2033formulationUS 11642317
  • May 3, 2033formulationUS 11872318
  • May 3, 2033formulationUS 11872318
  • May 3, 2033formulationUS 12115246
  • May 3, 2033formulationUS 12115246
  • May 3, 2033formulationUS 9056057
  • May 3, 2033formulationUS 9056057
  • May 3, 2033formulationUS 9393213
  • May 3, 2033formulationUS 9393213
  • May 3, 2033method-of-use (U-2491)US 9532955
  • May 3, 2033method-of-use (U-2491)US 9532955
  • May 3, 2033method-of-use (U-2492)US 9737491
  • May 3, 2033method-of-use (U-2492)US 9737491
  • May 3, 2033formulationUS 9827191
  • May 3, 2033formulationUS 9827191

FDA exclusivities (1)

  • Jul 14, 2026CGTCGT

News(0)

no news has mentioned this drug yet

brand
Inveltys
generic
loteprednol etabonate
indication
Ocular Inflammation
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 25m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?